Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prospective Randomized Study of Accelerated Radiation Therapy (PRART)
Sponsor: Weill Medical College of Cornell University
Summary
Patients with Stage 0 ductal carcinoma in situ (Tis (DCIS), Stage T1-T2, lymph node negative(N0) breast cancers will be randomized to receive whole breast radiotherapy with a concomitant boost to the tumor bed over 15 fractions (Arm 1, standard) versus 10 fractions (Arm 2, experimental).
Official title: Prospective Randomized Study of Accelerated Radiation Therapy (PRART) : A Non-Inferiority Trial to Compare Breast Cosmesis and Local Control After Concomitant Boost Breast Radiotherapy With Fifteen Fractions in Three Weeks (Arm 1, Standard) Versus Ten Fractions in Two Weeks (Arm 2, Experimental)
Key Details
Gender
FEMALE
Age Range
19 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2019-11-21
Completion Date
2030-06-30
Last Updated
2025-07-25
Healthy Volunteers
No
Conditions
Interventions
Radiation therapy - 3 weeks
Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions
Radiation therapy - 2 weeks
Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.
Locations (3)
New York Presbyterian Hospital at Lower Manhattan Cancer Center
New York, New York, United States
Brooklyn Methodist Hospital - NewYork Presbyterian
New York, New York, United States
New York Presbyterian Hospital - Queens
New York, New York, United States